|
|
Article: Sequenom ceo pursuing new product in volatile market: fast-growing biotech developing alternative to invasive prenatal tests.
- Article from:
- San Diego Business Journal
- Article date:
- February 9, 2009
- Author:
CopyrightCOPYRIGHT 2009 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Call it Wall Street's new baby.
During the worst financial crisis since the Great Depression, San Diego-based Sequenom watched as its stock shot up more than 100 percent last year to stake a claim as the region's top performer.
CEO Harry Stylli, who came to America from England in the early 1990s to help jump-start Aurora Biosciences, which later became Vertex Pharmaceuticals, said he doesn't put his faith in the volatile market, however.
[ILLUSTRATION OMITTED]
"The stock market can love us, hate us, find reasons to short us, invent reasons to short us, invent reasons to love us," he said. "They're very fickle friends."
...